Tevogen Bio Holdings Inc..
TVGN.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Tevogen Bio Holdings Inc. is a biotechnology company focused on developing allogeneic T cell immunotherapies for treating viral infections, cancers, and autoimmune diseases. Their primary focus is on developing off-the-shelf T cell therapies that are accessible to a broader patient population. The c...Show More
Better Health for All
10
Tevogen Bio's core business is the development of precision T cell therapies for infectious diseases, cancers, and neurological disorders.
1
Clinical trial data for TVGN 489, a SARS-CoV-2 specific therapy, showed symptom improvement and resolution in treatment arm patients, with 88% or greater viral elimination in 92% of patients by day +4, and over 99% viral elimination in all patients by day +14, with no progression of disease or Long COVID observed.
2
The company has no products with established negative health impacts. The TVGN 489 therapy was well-tolerated at all four doses tested in the Phase I clinical trial, with no dose-limiting toxicities or significant adverse events observed.
3
The company aims for affordability and accessibility, and its lead product, TVGN 489, is expected to yield hundreds of doses per lot, suggesting potential for broader access.
4
The development of TVGN 489 directly addresses the COVID-19 global health crisis.
5
The company holds three granted patents and twelve pending patents, including two related to artificial intelligence, but there is no information on patent flexibility or access frameworks.
6
While the company is in clinical trials, there is no specific data on the ethical conduct of these trials, such as diversity in trial populations or comprehensive results reporting beyond the positive outcomes.
Fair Money & Economic Opportunity
0
Tevogen Bio Holdings Inc. is a biotechnology company focused on developing T cell immunotherapies, not a financial institution.
1
The company does not engage in activities that lend, insure, move, or store money for consumers. Therefore, all KPIs related to financial products, services, and customer financial outcomes, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, profit reinvestment, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, are not applicable to its core business model.
Fair Pay & Worker Respect
-40
In 2024, the CEO's total compensation was 1,773 times the median U.S. worker's pay.
1
For the fiscal year ending 2024, CEO Ryan Saadi's total compensation was $87,764,783, which included a salary of $501,000 and $87,263,783 in stock awards.
2
This compensation is significantly above the average for CEOs in similarly sized US companies, which is $565.10K.
3
Fair Trade & Ethical Sourcing
0
The provided articles, including corporate governance guidelines, a code of business conduct and ethics, and company updates, do not contain any specific information or data points related to fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clauses in supplier contracts, the share of spend on high-risk materials, or supplier diversity spend. Therefore, no assessment can be made against the specified KPIs for Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No evidence available to assess Tevogen Bio Holdings Inc. on Honest & Fair Business.
Kind to Animals
0
No evidence available to assess Tevogen Bio Holdings Inc. on Kind to Animals.
No War, No Weapons
0
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company focused on developing T-cell immunotherapies for infectious diseases and cancers.
1
Its core business involves technologies like ExacTcell™, PredicTcell, and Tevogen.AI, developed in collaboration with Microsoft Azure, for medical applications such as COVID-19 and oncology.
2
The company has three granted patents and twelve pending ex-US patents, two of which are related to artificial intelligence.
3
There is no evidence in the provided articles to suggest any involvement in arms manufacturing, military contracts, dual-use technologies with military applications, or any other activities related to war or conflict.
4
Planet-Friendly Business
0
The provided articles do not contain specific, quantitative data or concrete actions related to any of the environmental performance metrics for Tevogen Bio Holdings Inc. Information regarding greenhouse gas emissions, renewable energy use, water consumption, waste diversion, green building certifications, climate targets, or any climate-related financial disclosures is not available.
1
While the company mentions a focus on "sustainability" and "cost-efficient business model" to ensure patient accessibility,
2
these are general statements and do not provide measurable environmental performance data for any of the specified KPIs.
Respect for Cultures & Communities
0
Tevogen Bio Holdings Inc. has no reported cultural appropriation incidents.
1
Its operations do not involve indigenous peoples, making FPIC processes and specific tracking of indigenous suppliers not applicable.
2
There are no reported cultural site disruptions, and no cultural incidents requiring a response have been mentioned.
3
The company's CEO made personal donations of shares to a local benevolent association
4
and a UN-recognized nonprofit supporting education for underprivileged children,
5
but this is not company revenue reinvested or charitable giving to cultural heritage organizations.
Safe & Smart Tech
-30
Tevogen Bio has reported no known material cybersecurity incidents or breaches as of February 4, 2026, covering the past three years.
1
The company also reports no incidents of unauthorized data use.
2
Users have rights to access, correct, update, erase, restrict, or receive their personal data in a usable electronic format, object to data use, and withdraw consent.
3
The company implements multi-factor authentication, but the availability for specific services is not detailed.
4
Critical vulnerabilities are patched within 21-30 days on average. Tevogen processes personal data to comply with legal or regulatory requirements.
5
Zero Waste & Sustainable Products
0
No evidence available to assess Tevogen Bio Holdings Inc. on Zero Waste & Sustainable Products.